Archived from the original on 26 March 2021. Archived from the original on 18 November 2015. Archived from the original on 6 November 2015. "Raleigh's Sprout Pharmaceuticals awaits FDA ruling on female libido drug".
- Flibanserin should be discontinued if no benefit is observed after several weeks.
- The medication's influence on mental health conditions is still being studied.
- Flibanserin was recognized as a breakthrough therapy for female sexual desire issues.
- Its use is guided by strict medical protocols due to safety concerns.
- Women are encouraged to report any adverse effects during treatment.
- Continued research aims to improve treatment options for female sexual health.
- Flibanserin is one of a few FDA-approved drugs for Female Sexual Desire Disorder.
- Clinical improvements may include increased frequency of satisfying sexual events.
- The drug's use should be combined with counseling when appropriate.
Archived from the original on 3 June 2019. "'Faux-advocacy,' not science, prompted FDA panel's OK of 'low libido' drug for women, critics charge". Archived from the original on 30 August 2015. "Evaluation of Flibanserin: Science and Advocacy at the FDA". ^ "Valeant - Valeant Pharmaceuticals to Acquire Sprout Pharmaceuticals". Archived from the original on 22 August 2015. Archived from the original on 17 November 2015. Archived from the original on 29 January 2021. Archived from the original on 26 October 2020. Sex, aggression and pair-bond: a study on the serotonergic regulation of female sexual function in the marmoset monkey (Thesis). "Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain". "Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety".
What women are saying
Archived from the original on 4 March 2021. "First drug to improve sexual desire in women approved in the United States". Archived from the original on 13 February 2021. Archived from the original on 7 April 2021. Approves Addyi, a Libido Pill for Women". "The Company Behind 'Female Viagra' Just Raised $20 Million in Funding".
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Original | 100mg | 8 Pills | 59.84€ 56.99€ | |
| Kamagra Gold | 100 mg | 120 + 6 Pills | 330.74€ 314.99€ | |
| Levitra Generic | 10mg | 30 + 4 Pills | 62.39€ 59.42€ | |
| Apcalis SX Oral Jelly | 20mg | 50 + 6 Sachets | 146.39€ 139.42€ | |
| Priligy Generic Dapoxetine | 60mg | 60 + 8 Pills | 183.06€ 174.34€ | |
| Cialis Black | 80mg | 360 + 20 Pills | 639.78€ 609.31€ | |
| Cialis Generic | 60mg | 270 + 10 Pills | 443.96€ 422.82€ | |
| Super Kamagra | 160 mg | 92 + 6 Pills | 478.75€ 455.95€ | |
| Tadalista Super Active | 20mg | 270 + 30 Pills | 661.49€ 629.99€ | |
| Cialis Generic | 60mg | 30 + 2 Pills | 85.33€ 81.27€ | |
| Kamagra Effervescent Tablets | 100 mg | 42 + 7 Pills | 122.97€ 117.11€ | |
| Kamagra Oral Jelly | 100 mg | 90 + 8 Sachets | 303.56€ 289.10€ | |
| Kamagra | 100mg | 60 + 4 Pills | 201.34€ 191.75€ | |
| Cialis Generic | 20mg | 270 + 10 Pills | 335.21€ 319.25€ |
"The Women's Libido Pill Is Back, and So Is the Controversy". Flibanserin is used to treat hypoactive sexual desire disorder (HSDD) in women younger than 65 years of age who have low sexual desire that is troubling to them and is not caused by a medical or mental problem, problems in the relationship, or medicine or other drug use.
- Reporting of adverse events is encouraged through the FDA MedWatch program.
- Healthcare providers should report syncope, severe hypotension, or liver injury.
- Post-marketing surveillance is critical for understanding rare, long-term risks.
- Drug utilization reviews track prescribing patterns and potential misuse.
- In case of suspected pregnancy, patients should contact their doctor immediately.
- Animal studies showed developmental toxicity at doses much higher than human dose.
- Lactation studies in animals showed excretion in milk; human data are lacking.
- Decision to breastfeed while on flibanserin requires weighing potential risks.
- The benefit for an individual patient must justify the potential risk to a fetus/infant.
Women who have gone through menopause and men should not use flibanserin. Do not use this medicine to improve sexual performance. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms: In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make.
How much does Addyi (flibanserin) cost?
Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. The dual control model: The role of sexual inhibition & excitation in sexual arousal and behavior In Janssen, E. (Ed). "Acute and repeated flibanserin administration in female rats modulates monoamines differentially across brain areas: a microdialysis study". "Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant".
What should I do if I accidentally use too much Addyi?
^ "18 June 2010 meeting of the FDA Advisory Committee for Reproductive Health Drugs" (PDF). Archived from the original (PDF) on 13 September 2016. ^ "Drug for sexual desire disorder opposed by panel". Archived from the original on 11 February 2021. ^ a b "Joint Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee" (PDF).
Brand Names: Canada
Archived from the men enhancement pills original (PDF) on 5 June 2015. Archived from the original on 15 October 2010. ^ "Sprout Pharmaceuticals resubmits flibanserin NDA for treating HSDD in pre-menopausal women". Archived from the original on 19 March 2025. Archived from the original on 10 August 2015. For this medicine, the following should be considered: Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines.
prescriptions written for Addyi*
The initial response since the 2015 introduction of flibanserin to the US market was slow with 227 prescriptions written during the first three weeks. [46] The slow response may be related to a number of factors: physicians require about 10 minutes of online training to get certified; the medication costs about US$400 per month;[47] and questions about the drug's efficacy and need. Archived from the original on 7 June 2022. Archived from the original on 20 October 2020. "Design of Phase III pivotal trials of flibanserin in female Hypoactive Sexual Desire Disorder (HSDD)".
Addyi affects
Archived (PDF) from the original on 14 November 2022. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association; 2000:493–538. "Nothing Is Wrong With Your Sex Drive". Archived from the original on 15 July 2017.
Flibanserin may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:
"Clinically Meaningful Benefit in Women with Hypoactive Sexual Desire Disorder Treated with Flibanserin". "In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre- and postsynaptic 5-HT1A receptors in the rat brain". "Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder". "Multifunctional pharmacology of flibanserin: possible mechanism of therapeutic action in hypoactive sexual desire disorder". "Flibanserin (Addyi): The First FDA-Approved Treatment for Female Sexual Interest/Arousal Disorder in Premenopausal Women". Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Flibanserin should never be used in children for HSDD. Flibanserin is not recommended for use in the elderly.
| Issue | Description |
|---|---|
| Efficacy Debate | Some experts question the clinical significance of benefits |
| Side Effect Concerns | Risks of hypotension, syncope, and severe allergic reactions |
| Marketing & Approval Controversies | Criticism over FDA approval process and marketing practices |
| Post-Marketing Surveillance | Ongoing monitoring for rare adverse events |
Safety and efficacy have not been established. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur.
| Country | Approval Status | Year |
|---|---|---|
| United States | Approved | 2015 |
| Canada | Approved | 2016 |
| European Union | Pending/Under review | N/A |
| Australia | Not approved | N/A |
In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below.
Before using flibanserin
In December 2013, a Formal Dispute Resolution was filed,[30] which contained the requirements of the FDA for further studies. These include two studies in healthy subjects to determine if flibanserin impairs their ability to drive, and to determine if it interferes with other biochemical pathways. The Agency agreed to call a new Advisory Committee meeting to consider whether the risk-benefit ratio of flibanserin was favorable after this additional data was obtained. In June 2015, the US FDA Advisory Committee, which includes the Bone, Reproductive, and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSRM), recommended approval of the drug by 18–6, with the proviso that measures be taken to inform women of the drug's side effects. [33][34] On 18 August 2015, the FDA approved Addyi (flibanserin) for the treatment of premenopausal women with low sexual desire that causes personal distress or relationship difficulties.
Less common
The approval specified that flibanserin should not be used to treat low sexual desire caused by co-existing psychiatric or medical problems; low sexual desire caused by problems in the relationship; or low sexual desire due to medication side effects. As of August 2015, Sprout Pharmaceuticals had not yet made an application to the European Medicines Agency for a marketing authorization. Even the Score, a coalition of women's groups brought together by a Sprout consultant, actively campaigned for the approval of flibanserin. The campaign emphasized that several approved treatments for male sexual dysfunction exist, while no such treatment for women was available. [36] The group successfully obtained letters of support from the President of the National Organization for Women, the editor of the Journal of Sexual Medicine, and several members of Congress.
Dosage forms and strengths (USA)
Other organizations supporting the approval of flibanserin included the National Council of Women's Organizations, the Black Women's Health Imperative, the Association of Reproductive Health Professionals, National Consumers League, and the American Sexual Health Association. The approval was opposed by the National Women's Health Network, the National Center for Health Research and Our Bodies Ourselves. [42] A representative of PharmedOut said "To approve this drug will set the worst kind of precedent—that companies that spend enough money can force the FDA to approve useless or dangerous drugs. "[43] An editorial in JAMA noted that, "Although flibanserin is not the first product to be supported by a consumer advocacy group in turn supported by pharmaceutical manufacturers, claims of gender bias regarding the FDA's regulation have been particularly noteworthy, as have the extent of advocacy efforts ranging from social media campaigns to letters from members of Congress". In August 2015, Valeant Pharmaceuticals and Sprout Pharmaceuticals announced that Valeant will acquire Sprout, on a debt-free basis, for approximately $1 billion in cash, plus a share of future profits based upon the achievement of certain milestones. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive. Using this medicine with any of the following medicines is not recommended.
Warnings & Precautions
^ FDA seeks more tests on a female Viagra, by Matthew Perrone, The Detroit Free Press, page 2A Wednesday, 12 February 2014 "FDA: Female sex drive drug needs more research - CNN.com". Archived from the original on 1 August 2017. "Advisers To FDA Recommend Agency Approve Drug To Boost Female Libido". Archived from the original on 4 June 2015. ^ "Critics: Women's Sex Pill Approval Vote Driven By PR, Not Science". Your doctor may decide not to treat you with this medication or change some of the other medicines you take. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.